BridgeBio Pharma Inc’s recent filing unveils that its Director Ellis Andrea unloaded Company’s shares for reported $1.02 million on Apr 01 ’25. In the deal valued at $34.05 per share,30,000 shares were sold. As a result of this transaction, Ellis Andrea now holds 12,000 shares worth roughly $0.41 million.
Then, ANDREA ELLIS bought 30,000 shares, generating $1,021,500 in total proceeds.
Before that, Kumar Neil sold 75,000 shares. BridgeBio Pharma Inc shares valued at $2,764,943 were divested by the Chief Executive Officer at a price of $36.87 per share. As a result of the transaction, Kumar Neil now holds 4,948,447 shares, worth roughly $167.8 million.
Redburn Atlantic initiated its BridgeBio Pharma Inc [BBIO] rating to a Buy in a research note published on March 31, 2025; the price target was $50. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Oppenheimer began covering BBIO with “Perform” recommendation on October 03, 2024. Piper Sandler started covering the stock on September 04, 2024. It rated BBIO as “an Overweight”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 4.95% to $33.91. Over the last five days, the stock has gained 8.10%. BridgeBio Pharma Inc shares have risen nearly 23.58% since the year began. Nevertheless, the stocks have risen 24.08% over the past one year. While a 52-week high of $39.47 was reached on 02/20/25, a 52-week low of $21.62 was recorded on 01/02/25. SMA at 50 days reached $33.60, while 200 days put it at $28.62.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 32.51, which if violated will result in even more drops to 31.12. On the upside, there is a resistance level at 34.69. A further resistance level may holdings at 35.48. The Relative Strength Index (RSI) on the 14-day chart is 51.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.61%. Stochastics %K at 49.72% indicates the stock is a holding.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-03-31, dropping by -0.45 million shares to a total of 21.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 22.16 million shares. There was a decline of -2.06%, which implies that there is a negative sentiment for the stock.
